0

Cardiovascular and Metabolic Disease Center
Mitochondrial Research Affinity Collaboration-Laboratories & Engineering

Home > 0

Levitra May Protect The Heart, VCU Study Shows a protective effect against heart attack injury by opening the mitochondrial KATP channel

  • 작성자한진
  • 작성일2006-02-26 02:42:56
  • 조회수4583
  • 첨부파일첨부파일
The widely used erectile dysfunction drug Levitra is now the second drug in its class found to protect the heart against tissue damage following acute heart attack, according to a new study by Virginia Commonwealth University researchers. "Our findings further support the concept that the novel class of phosphodiesterase-5 inhibitors, or PDE-5 inhibitors, including Levitra and Viagra, may have a new utility in cardiac protection, in addition to their well-known use for the management of erectile dysfunction in men," said Rakesh C. Kukreja, Ph.D., professor of medicine, physiology, biochemistry and emergency medicine at VCU. Kukreja is lead author of the study. In the study, currently available online and to be published in the March issue of the Journal of Molecular and Cellular Cardiology, Kukreja and his team demonstrated for the first time that pretreatment with a clinically relevant dose of Levitra, generically known as vardenafil, induces a protective effect against heart attack injury by opening the mitochondrial KATP channel in an animal model. The Journal of Molecular and Cellular Cardiology is the official publication of the International Society for Heart Research. According to Kukreja, PDE-5 is an enzyme responsible for the destruction of cGMP, an intracellular messenger molecule, in heart cells. He said that the mitochondrial KATP channel and cGMP play an important role in preconditioning of the heart following a heart attack. The cGMP also has a hand in the dilation of arteries in the body. PDE-5 inhibitor drugs, such as vardenafil, sildenafil, the generic term for Viagra, and tadalafil, the generic name for Cialis, are able to preserve cGMP, and therefore dilation of the arteries by inhibiting PDE-5. Vardenafil, like sildenafil, stabilizes the mitochondria and protects against damage of the heart by opening the mitochondrial KATP channels in cardiac cells. Mitochondria are cellular organelles critical for converting oxygen into ATP, the key fuel for cellular function. "This study provides important information about the mechanism by which the PDE-5 inhibitors work. Furthermore, it is proof that the positive findings of prior studies on sildenafil extend to another PDE-5 inhibitor," said George Vetrovec, M.D., chair of cardiology at VCU's School of Medicine, who is internationally recognized for his research on coronary artery disease. Vetrovec suggested that PDE-5 inhibitors such as sildenafil and vardenafil may one day be given to patients who are at high risk for acute heart attack or prior to undergoing coronary artery bypass surgery to optimize heart protection. In addition, Kukreja said that the PDE-5 inhibitors may be developed for future use to protect the brain, liver and other organs against ischemic injury – those injuries that are caused by lack of oxygen. Kukreja and his colleagues began studying sildenafil in 2002 as part of ongoing research into "preconditioning," a way to protect the heart muscle from serious damage in the future by subjecting it to very brief periods of deprivation of blood flow and, therefore, oxygen. ### This work was supported by a grant from the National Institutes of Health. Kukreja collaborated with VCU researchers, Fadi N. Salloum, Ph.D., Ramzi A. Ockaili Ph.D., Michael Wittkamp Ph.D., and Vijay R. Marwaha, Ph.D. About VCU and the VCU Medical Center: Located on two downtown campuses in Richmond, Va., Virginia Commonwealth University is ranked nationally by the Carnegie Foundation as a top research institution and enrolls more than 29,000 students in more than 181 certificate, undergraduate, graduate, professional and doctoral programs in the arts, sciences and humanities in 15 schools and one college. Forty of the university's programs are unique in Virginia, and 20 graduate and professional programs have been ranked by U.S. News & World Report as among the best of their kind. MCV Hospitals, clinics and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the leading academic medical centers in the country. For more, see http://www.vcu.edu/. Contact: Sathya Achia-Abraham sbachia@vcu.edu Virginia Commonwealth University
Total405 [ page1/27 ]
No. 제목 작성자 작성일 조회수
405 인제대 의과대학 김형규 교수, 생리학 분야 최고 학술상 수상 2023.11.09 관리자 2023.11.09 44
404 인제대, 과기정통부 ‘2023년도 기초연구실 지원사업’ 선정 2023.09.13 관리자 (web_admin) 2023.09.13 81
403 인제대 교수팀 '돌연사 주범 심부전 원인 규명' 2023.09.13 관리자 (web_admin) 2023.09.13 70
402 2022학년도 인제학술상 수상자 선정 결과 2023.01.05 관리자 2023.01.05 107
401 안전관리 우수연구실 인증 취득 2023.01.05 관리자 2023.01.05 62
400 한진교수 화의자의학상 수상 2023.01.05 관리자 2023.01.05 119
399 이온통로 학회 -Amy 포스터상 수상 2019.01.15 김형규 2019.01.15 2,602
398 센터 겸임교수 조성우 교수 - 한빛사 -JACC Vascular Imaging 2018.12.08 김형규 2018.12.08 2,815
397 2017 IMPACT Symposium 개최 첨부파일 2017.10.31 김보현 2017.10.31 2,602
396 경암바이오유스 2017 첨부파일 2017.08.11 김보현 2017.08.11 2,885
395 KORUS 2017 첨부파일 2017.06.21 김보현 2017.06.21 3,005
394 IMPACT 2016 심포지엄 개최 안내 첨부파일 2016.04.18 관리자 2016.04.18 4,019
393 IMPACT 2015 심포지엄 개최 안내 첨부파일 2015.04.20 서대윤 2015.04.20 2,880
392 2015 중점연구소 성과 전시회 첨부파일 2015.03.31 김형규 2015.03.31 2,472
391 Best Miso Award - 한진 2014.11.04 이정훈 2014.11.04 2,081
처음이전1 2 3 4 5 6 7 8 9 10 다음 마지막